Compare Enveric Biosciences Inc (ENVB) vs Tenaris S.A. American Depositary Shares (TS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Tenaris S.A. American Depositary Shares — how do they compare? Enveric Biosciences Inc trades at $1.2 (market cap $6.27M), while Tenaris S.A. American Depositary Shares trades at $58.11 (market cap $29.31B). The key difference: Tenaris S.A. American Depositary Shares is far larger — about 4674.6× Enveric Biosciences Inc's market cap, and Tenaris S.A. American Depositary Shares pays a 4.07% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Tenaris S.A. American Depositary Shares for 0 Days on average.
| ENVB | TS | |
|---|---|---|
Market Cap | $6.27M | $29.31B |
Volume | 100,675 | 802,043 |
Sector | Health | Energy |
52-Week High | $10.80 | $64.02 |
52-Week Low | $1.27 | $34.28 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$2.03M | $26.97B |
Dividend Yield | — | 4.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.40, down 4.76% with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and no revenue in 2025, though it has consistently beaten EPS estimates. Recent news highlights patent approvals and positive preclinical data for its neuroplastogenic therapeutics.
The outlook remains speculative given the lack of revenue and negative cash flow from operations. Analyst consensus is 75% buy, but high business execution risks and dependence on drug development success pose significant challenges for near-term shareholder value.
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Tenaris S.A. American Depositary Shares
Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →
